Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

被引：16

作者：

Ardini, Elena ^{[1
]}

Siena, Salvatore ^{[2
]}

机构：

[1] Nerviano Med Sci Srl, Nerviano, Lombardia, Italy

[2] Univ Milan, Oncol & Hemato Oncol, Milan, Italy

来源：

ESMO OPEN | 2020年 / 5卷 / 05期

基金：

欧盟地平线“2020”;

关键词：

entrectinib; NTRK inhibitor; ROS1; inhibitor; cancer therapy; INTEGRATED ANALYSIS; ALK INHIBITOR; PAN-TRK; TROPOMYOSIN; FUSION; DISCOVERY;

D O I：

10.1136/esmoopen-2020-000867

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页数：4

共 14 条

[1] Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer [J].

Amatu, A. ;

Sartore-Bianchi, A. ;

Bencardino, K. ;

Pizzutilo, E. G. ;

Tosi, F. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2019, 30 :VIII5-VIII15

[2] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications [J].

Ardini, Elena ;

Menichincheri, Maria ;

Banfi, Patrizia ;

Bosotti, Roberta ;

De Ponti, Cristina ;

Pulci, Romana ;

Ballinari, Dario ;

Ciomei, Marina ;

Texido, Gemma ;

Degrassi, Anna ;

Avanzi, Nilla ;

Amboldi, Nadia ;

Saccardo, Maria Beatrice ;

Casero, Daniele ;

Orsini, Paolo ;

Bandiera, Tiziano ;

Mologni, Luca ;

Anderson, David ;

Wei, Ge ;

Harris, Jason ;

Vernier, Jean-Michel ;

Li, Gang ;

Felder, Eduard ;

Donati, Daniele ;

Isacchi, Antonella ;

Pesenti, Enrico ;

Magnaghi, Paola ;

Galvani, Arturo .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (04) :628-639

[3] The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition [J].

Ardini, Elena ;

Bosotti, Roberta ;

Borgia, Andrea Lombardi ;

De Ponti, Cristina ;

Somaschini, Alessio ;

Cammarota, Rosaria ;

Amboldi, Nadia ;

Raddrizzani, Laura ;

Milani, Andrea ;

Magnaghi, Paola ;

Ballinari, Dario ;

Casero, Daniele ;

Gasparri, Fabio ;

Banfi, Patrizia ;

Avanzi, Nilla ;

Saccardo, Maria B. ;

Alzani, Rachele ;

Bandiera, Tiziano ;

Felder, Eduard ;

Donati, Daniele ;

Pesenti, Enrico ;

Sartore-Bianchi, Andrea ;

Gambacorta, Marcello ;

Pierotti, Marco A. ;

Siena, Salvatore ;

Veronese, Silvio ;

Galvani, Arturo ;

Isacchi, Antonella .

MOLECULAR ONCOLOGY, 2014, 8 (08) :1495-1507

[4] On the right TRK: from oncogene discovery to cancer therapeutics FOREWORD [J].

Barbacid, M. .

ANNALS OF ONCOLOGY, 2019, 30 :VIII3-VIII4

[5] STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions [J].

Desai, Ami V. ;

Brodeur, Garrett M. ;

Foster, Jennifer ;

Shusterman, Suzanne ;

Sabnis, Amit J. ;

Macy, Magaret ;

Wetmore, Cynthia ;

Basu, Ellen ;

Hornby, Zachary ;

Esquibel, Vanessa ;

Maneval, Edna Chow ;

Multani, Pratik S. ;

Fox, Elizabeth .

CANCER RESEARCH, 2017, 77

[6] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [J].

Doebele, Robert C. ;

Drilon, Alexander ;

Paz-Ares, Luis ;

Siena, Salvatore ;

Shaw, Alice T. ;

Farago, Anna F. ;

Blakely, Collin M. ;

Seto, Takashi ;

Cho, Byung Chul ;

Tosi, Diego ;

Besse, Benjamin ;

Chawla, Sant P. ;

Bazhenova, Lyudmila ;

Krauss, John C. ;

Chae, Young Kwang ;

Barve, Minal ;

Garrido-Laguna, Ignacio ;

Liu, Stephen V. ;

Conkling, Paul ;

John, Thomas ;

Fakih, Marwan ;

Sigal, Darren ;

Loong, Herbert H. ;

Buchschacher, Gary L., Jr. ;

Garrido, Pilar ;

Nieva, Jorge ;

Steuer, Conor ;

Overbeck, Tobias R. ;

Bowles, Daniel W. ;

Fox, Elizabeth ;

Riehl, Todd ;

Chow-Maneval, Edna ;

Simmons, Brian ;

Cui, Na ;

Johnson, Ann ;

Eng, Susan ;

Wilson, Timothy R. ;

Demetri, George D. .

LANCET ONCOLOGY, 2020, 21 (02) :271-282

[7] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials [J].

Drilon, Alexander ;

Siena, Salvatore ;

Dziadziuszko, Rafal ;

Barlesi, Fabrice ;

Krebs, Matthew G. ;

Shaw, Alice T. ;

de Braud, Filippo ;

Rolfo, Christian ;

Ahn, Myung-Ju ;

Wolf, Juergen ;

Seto, Takashi ;

Cho, Byoung Chul ;

Patel, Manish R. ;

Chiu, Chao-Hua ;

John, Thomas ;

Goto, Koichi ;

Karapetis, Christos S. ;

Arkenau, Hendrick-Tobias ;

Kim, Sang-We ;

Ohe, Yuichiro ;

Li, Yu-Chung ;

Chae, Young K. ;

Chung, Christine H. ;

Otterson, Gregory A. ;

Murakami, Haruyasu ;

Lin, Chia-Chi ;

Tan, Daniel S. W. ;

Prenen, Hans ;

Riehl, Todd ;

Chow-Maneval, Edna ;

Simmons, Brian ;

Cui, Na ;

Johnson, Ann ;

Eng, Susan ;

Wilson, Timothy R. ;

Doebele, Robert C. .

LANCET ONCOLOGY, 2020, 21 (02) :261-270

[8] Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) [J].

Drilon, Alexander ;

Siena, Salvatore ;

Ou, Sai-Hong Ignatius ;

Patel, Manish ;

Ahn, Myung Ju ;

Lee, Jeeyun ;

Bauer, Todd M. ;

Farago, Anna F. ;

Wheler, Jennifer J. ;

Liu, Stephen V. ;

Doebele, Robert ;

Giannetta, Laura ;

Cerea, Giulio ;

Marrapese, Giovanna ;

Schirru, Michele ;

Amatu, Alessio ;

Bencardino, Katia ;

Palmeri, Laura ;

Sartore-Bianchi, Andrea ;

Vanzulli, Angelo ;

Cresta, Sara ;

Damian, Silvia ;

Duca, Matteo ;

Ardini, Elena ;

Li, Gang ;

Christiansen, Jason ;

Kowalski, Karey ;

Johnson, Ann D. ;

Patel, Rupal ;

Luo, David ;

Chow-Maneval, Edna ;

Hornby, Zachary ;

Multani, Pratik S. ;

Shaw, Alice T. ;

De Braud, Filippo G. .

CANCER DISCOVERY, 2017, 7 (04) :400-409

[9] ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research [J].

Marchio, C. ;

Scaltriti, M. ;

Ladanyi, M. ;

Iafrate, A. J. ;

Bibeau, F. ;

Dietel, M. ;

Hechtman, J. F. ;

Troiani, T. ;

Lopez-Rios, F. ;

Douillard, J-Y. ;

Andre, F. ;

Reis-Filho, J. S. .

ANNALS OF ONCOLOGY, 2019, 30 (09) :1417-1427

[10] A HUMAN ONCOGENE FORMED BY THE FUSION OF TRUNCATED TROPOMYOSIN AND PROTEIN TYROSINE KINASE SEQUENCES [J].

MARTINZANCA, D ;

HUGHES, SH ;

BARBACID, M .

NATURE, 1986, 319 (6056) :743-748

← 1 2 →